Skip to main content
Top
Published in: Clinical & Experimental Metastasis 1-2/2018

01-02-2018 | Research Paper

Time-dependent change in relapse sites of renal cell carcinoma after curative surgery

Authors: Go Noguchi, Noboru Nakaigawa, Masataka Taguri, Sohgo Tsutsumi, Yoko Saito, Sachi Fukui, Masato Yasui, Takashi Tokita, Taku Mitome, Tomoyuki Tatenuma, Shinnosuke Kuroda, Koichi Abe, Daiki Ueno, Kazuhiro Namura, Susumu Umemoto, Akitoshi Takizawa, Junichi Ohta, Teiichiro Ueki, Takeshi Watanabe, Kazuki Kobayashi, Keiichi Kondo, Takeshi Kishida, Hitomi Kanno, Kazuo Kitami, Takeharu Yamanaka, Masahiro Yao

Published in: Clinical & Experimental Metastasis | Issue 1-2/2018

Login to get access

Abstract

We investigated time-dependent changes in the relapse features of renal cell carcinoma (RCC) after curative surgery. Between 1985 and 2015, 1398 patients with RCC (1226 clear cell RCC, 89 papillary RCC, and 53 chromophobe RCC) underwent curative surgery at Yokohama City University Hospital and its affiliated hospitals. We retrospectively reviewed the clinicopathologic factors of patients with relapse after surgery. Median follow-up was 56.3 months. Recurrence occurred in 245 patients (217 clear cell RCC, 12 papillary RCC, and 3 chromophobe RCC). Papillary RCC and chromophobe RCC had no recurrence beyond 5 years after surgery, but 20 cases of clear cell carcinoma had recurrence beyond 10 years after surgery. The typical recurrence sites of clear cell RCC were lung (46.6%), bone (17.9%), liver (7.6%), and lymph nodes (6.5%). The proportion of recurrences at these typical sites was 83.9% for recurrences within 5 years, 76.3% between 5 and 10 years, and 40.0% beyond 10 years. In contrast, the proportion of retroperitoneal organ recurrence, including contralateral kidney, pancreas, and adrenal glands, increased with increasing time after surgery. Interestingly, the hazard ratio of typical site relapse decreased whereas that of retroperitoneal organ relapse increased in a time-dependent manner. In summary, clear cell RCC showed potential to relapse beyond 10 years after surgery. Recurrence at typical sites decreased whereas retroperitoneal organ recurrence increased in a time-dependent manner. Clinicians should check for recurrence at various sites beyond 10 years, especially in clear cell RCC.
Literature
2.
go back to reference Garcia JA, Rini BI (2007) Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 57:112–125CrossRefPubMed Garcia JA, Rini BI (2007) Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 57:112–125CrossRefPubMed
3.
go back to reference Sun M, Thuret R, Abdollah F et al (2011) Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 59:135–141CrossRefPubMed Sun M, Thuret R, Abdollah F et al (2011) Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 59:135–141CrossRefPubMed
4.
go back to reference Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS (2005) Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174:466–472CrossRefPubMed Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS (2005) Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174:466–472CrossRefPubMed
5.
go back to reference Leibovich BC, Blute ML, Cheville JC et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97:1663–1671CrossRefPubMed Leibovich BC, Blute ML, Cheville JC et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97:1663–1671CrossRefPubMed
6.
go back to reference Adamy A, Chong KT, Chade D et al (2011) Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 185:433–438CrossRefPubMed Adamy A, Chong KT, Chade D et al (2011) Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 185:433–438CrossRefPubMed
7.
go back to reference Brookman-May S, May M, Shariat SF et al (2013) Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol 64:472–477CrossRefPubMed Brookman-May S, May M, Shariat SF et al (2013) Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol 64:472–477CrossRefPubMed
9.
go back to reference Antonelli A, Furlan M, Sodano M et al (2016) Features, risk factors and clinical outcome of “very late” recurrences after surgery for localized renal carcinoma: a retrospective evaluation of a cohort with a minimum of 10 years of follow up. Int J Urol 23:36–40CrossRefPubMed Antonelli A, Furlan M, Sodano M et al (2016) Features, risk factors and clinical outcome of “very late” recurrences after surgery for localized renal carcinoma: a retrospective evaluation of a cohort with a minimum of 10 years of follow up. Int J Urol 23:36–40CrossRefPubMed
10.
go back to reference Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumors, 7th edn. Willey, Hoboken Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumors, 7th edn. Willey, Hoboken
11.
go back to reference Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) Pathology and genetics. Tumors of the urinary system and male genital organs. IARC Press, Lyon Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) Pathology and genetics. Tumors of the urinary system and male genital organs. IARC Press, Lyon
12.
go back to reference Hoffmann NE, Gillett MD, Cheville JC et al (2008) Differences in organ system of distant metastasis by renal cell carcinoma subtype. J Urol 179:474–477CrossRefPubMed Hoffmann NE, Gillett MD, Cheville JC et al (2008) Differences in organ system of distant metastasis by renal cell carcinoma subtype. J Urol 179:474–477CrossRefPubMed
14.
go back to reference Nishimura R, Osako T, Nishiyama Y et al (2013) Evaluation of factors related to late recurrence-later than 10 years after the initial treatment-in primary breast cancer. Oncology 85:100–110CrossRefPubMed Nishimura R, Osako T, Nishiyama Y et al (2013) Evaluation of factors related to late recurrence-later than 10 years after the initial treatment-in primary breast cancer. Oncology 85:100–110CrossRefPubMed
15.
go back to reference Sahdev A, Hughes JH, Barwick T et al (2007) Computed tomography features of recurrent ovarian carcinoma according to time to relapse. Acta Radiol 48:1038–1044CrossRefPubMed Sahdev A, Hughes JH, Barwick T et al (2007) Computed tomography features of recurrent ovarian carcinoma according to time to relapse. Acta Radiol 48:1038–1044CrossRefPubMed
16.
go back to reference Callaway MP, Briggs JC (1989) The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast Surg 42(1):46–49CrossRefPubMed Callaway MP, Briggs JC (1989) The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast Surg 42(1):46–49CrossRefPubMed
18.
go back to reference Staehler M (2011) The role of metastasectomy in metastatic renal cell carcinoma. Nat Rev Urol 8:180–181CrossRefPubMed Staehler M (2011) The role of metastasectomy in metastatic renal cell carcinoma. Nat Rev Urol 8:180–181CrossRefPubMed
19.
go back to reference Tosco L, Van Poppel H, Frea B (2013) Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur Urol 63:646–652CrossRefPubMed Tosco L, Van Poppel H, Frea B (2013) Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur Urol 63:646–652CrossRefPubMed
20.
go back to reference Naito S, Kinoshita H, Kondo T et al (2013) Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology 82:846–851CrossRefPubMed Naito S, Kinoshita H, Kondo T et al (2013) Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology 82:846–851CrossRefPubMed
21.
go back to reference Donat SM, Diaz M, Bishoff JT et al (2013) Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol 190:407–416CrossRefPubMed Donat SM, Diaz M, Bishoff JT et al (2013) Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol 190:407–416CrossRefPubMed
23.
go back to reference Stewart SB, Thompson RH, Psutka SP et al (2014) Evaluation of the national comprehensive cancer network and american urological association renal cell carcinoma surveillance guidelines. J Clin Oncol 32:4059–4065CrossRefPubMedPubMedCentral Stewart SB, Thompson RH, Psutka SP et al (2014) Evaluation of the national comprehensive cancer network and american urological association renal cell carcinoma surveillance guidelines. J Clin Oncol 32:4059–4065CrossRefPubMedPubMedCentral
Metadata
Title
Time-dependent change in relapse sites of renal cell carcinoma after curative surgery
Authors
Go Noguchi
Noboru Nakaigawa
Masataka Taguri
Sohgo Tsutsumi
Yoko Saito
Sachi Fukui
Masato Yasui
Takashi Tokita
Taku Mitome
Tomoyuki Tatenuma
Shinnosuke Kuroda
Koichi Abe
Daiki Ueno
Kazuhiro Namura
Susumu Umemoto
Akitoshi Takizawa
Junichi Ohta
Teiichiro Ueki
Takeshi Watanabe
Kazuki Kobayashi
Keiichi Kondo
Takeshi Kishida
Hitomi Kanno
Kazuo Kitami
Takeharu Yamanaka
Masahiro Yao
Publication date
01-02-2018
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 1-2/2018
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-018-9883-0

Other articles of this Issue 1-2/2018

Clinical & Experimental Metastasis 1-2/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine